| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
222 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro
|
Korfee, S.
|
|
2006
|
54 |
S1 |
p. S54-
1 p.
|
artikel
|
| 2 |
243 A case of malignant mesothelioma with rhabdomyosarcomatous differentiation
|
Rizvi, S.M.H.
|
|
2006
|
54 |
S1 |
p. S59-
1 p.
|
artikel
|
| 3 |
237 Accuracy of pathological diagnosis of mesothelioma (MM) in Japan
|
Inai, K.
|
|
2006
|
54 |
S1 |
p. S57-
1 p.
|
artikel
|
| 4 |
138 A cluster of five cases of malignant pleural mesothelioma among the faculty of a university asbestos insulated campus
|
Goldberg, M.
|
|
2006
|
54 |
S1 |
p. S34-
1 p.
|
artikel
|
| 5 |
210 A comparison of CALGB and EORTC paradigms in the assessment of ONCONASE for the treatment of unresectable malignant mesothelioma (UMM)
|
von Pawel, J.
|
|
2006
|
54 |
S1 |
p. S51-
1 p.
|
artikel
|
| 6 |
18 A conditional knockout model for malignant mesothelioma. A model for in vivo and in vitro therapeutic strategies
|
Jongsma, J.
|
|
2006
|
54 |
S1 |
p. S5-
1 p.
|
artikel
|
| 7 |
226 Activation of 4E-BP1 represses IGF-1 mediated capdependent translation in malignant pleural mesothelioma
|
Jacobson, B.A.
|
|
2006
|
54 |
S1 |
p. S55-
1 p.
|
artikel
|
| 8 |
40 Age and sex differences in malignant mesothelioma after residential exposure to blue asbestos (crocidolite)
|
Reid, A.
|
|
2006
|
54 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 9 |
110 Aggressive surgical cytoreduction with hyperthermic intraperitoneal chemoperfusion for patients with malignant mesothelioma
|
Pingpank, J.
|
|
2006
|
54 |
S1 |
p. S27-S28
2 p.
|
artikel
|
| 10 |
10 ALA mediated fluorescence thoracoscopy in pleural diseases
|
Burgers, S.
|
|
2006
|
54 |
S1 |
p. S3-
1 p.
|
artikel
|
| 11 |
93 Alterations of the G1 checkpoints in malignant pleural mesothelioma (MPM) in relation to pathogenesis and survival
|
Bahnassy, A.A.
|
|
2006
|
54 |
S1 |
p. S23-
1 p.
|
artikel
|
| 12 |
48 Altering the tumor microenvironment to augment immunotherapy for mesothelioma
|
Albelda, S.M.
|
|
2006
|
54 |
S1 |
p. S12-
1 p.
|
artikel
|
| 13 |
4 A mouse model recapitulating genetic and signaling perturbations characteristic of human mesothelioma
|
Testa, J.
|
|
2006
|
54 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 14 |
153 Analysis of NAT2 genotypes as risk factors for asbestosrelated malignant mesothelioma (MM) in a general population study
|
Betti, M.
|
|
2006
|
54 |
S1 |
p. S38-
1 p.
|
artikel
|
| 15 |
160 An apoptosis primer
|
Fennell, D.A.
|
|
2006
|
54 |
S1 |
p. S39-
1 p.
|
artikel
|
| 16 |
198 An epigenetic mechanism for capecitabine resistance in mesothelioma
|
Kosuri, K.V.
|
|
2006
|
54 |
S1 |
p. S48-
1 p.
|
artikel
|
| 17 |
206 Angiogenesis in mesothelioma
|
Dubey, S.
|
|
2006
|
54 |
S1 |
p. S50-
1 p.
|
artikel
|
| 18 |
94 An integrated analysis of chromosomal alteration and gene expression in malignant mesothelioma
|
Diyagama, D.S.
|
|
2006
|
54 |
S1 |
p. S23-
1 p.
|
artikel
|
| 19 |
103 An integrated genomic approach to understanding the determinants of mesothelioma sensitivity to specific novel agents
|
Shimizu, S.
|
|
2006
|
54 |
S1 |
p. S25-
1 p.
|
artikel
|
| 20 |
98 Anoikis resistance in malignant pleural mesothelioma cells
|
Daubriac, J.
|
|
2006
|
54 |
S1 |
p. S24-
1 p.
|
artikel
|
| 21 |
25 A novel murine mesothelioma model of malignant pleural effusion
|
Anraku, M.
|
|
2006
|
54 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 22 |
164 A novel role of the death receptor CD95 as a tumor promotor
|
Peter, M.E.
|
|
2006
|
54 |
S1 |
p. S40-
1 p.
|
artikel
|
| 23 |
220 A novel small molecule inhibitor of TGFβ type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection
|
Suzuki, E.
|
|
2006
|
54 |
S1 |
p. S53-S54
2 p.
|
artikel
|
| 24 |
16 An SV40 TAg transgenic model of asbestos-induced mesothelioma
|
Lake, R.A.
|
|
2006
|
54 |
S1 |
p. S4-
1 p.
|
artikel
|
| 25 |
50 Antibody-based treatment for mesothelioma: Clinical trials and laboratory studies
|
Hassan, R.
|
|
2006
|
54 |
S1 |
p. S13-
1 p.
|
artikel
|
| 26 |
58 A photodynamic therapy (PDT) generated tumor vaccine in an orthotopic murine malignant mesothelioma model
|
Friedberg, J.S.
|
|
2006
|
54 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 27 |
221 A randomized phase II trial of pegylated arginine deaminase (ADI-PEG 20) in patients with malignant pleural mesothelioma
|
Szlosarek, P.W.
|
|
2006
|
54 |
S1 |
p. S54-
1 p.
|
artikel
|
| 28 |
60 Asbestos-associatedmalignancies in the lung and pleura show distinct genetic aberrations
|
Lindholm, P.
|
|
2006
|
54 |
S1 |
p. S15-
1 p.
|
artikel
|
| 29 |
85 Asbestos burden, epigenetic silencing, and survival in malignant pleural mesothelioma
|
Christensen, B.C.
|
|
2006
|
54 |
S1 |
p. S21-
1 p.
|
artikel
|
| 30 |
59 Asbestos, chromosomal deletions and tumor suppressor gene alterations in human malignant mesothelioma
|
Jaurand, M.-C.
|
|
2006
|
54 |
S1 |
p. S15-
1 p.
|
artikel
|
| 31 |
73 Asbestos disease: A Canadian case study
|
Mackenzie, J.R.
|
|
2006
|
54 |
S1 |
p. S18-
1 p.
|
artikel
|
| 32 |
148 Asbestos exposure and genetic susceptibility to malignant pleural mesothelioma
|
Karageorgi, S.
|
|
2006
|
54 |
S1 |
p. S36-S37
2 p.
|
artikel
|
| 33 |
213 Asbestos in the past, nanomaterials in the future?
|
Sanchez, V.C.
|
|
2006
|
54 |
S1 |
p. S52-
1 p.
|
artikel
|
| 34 |
146 Asbestos problems in India: A revisit
|
Subramanian, V.
|
|
2006
|
54 |
S1 |
p. S36-
1 p.
|
artikel
|
| 35 |
43 Asbestos-related diseases from environmental exposure to crocidolite in Da-yao, China. II. An update study on mesothelioma and lung cancer mortality from a residentially exposed cohort and from local surveys and statistics
|
Wen, C.P.
|
|
2006
|
54 |
S1 |
p. S11-
1 p.
|
artikel
|
| 36 |
44 Asbestos use in India: Magnitude of risk and impact on health
|
Joshi, T.K.
|
|
2006
|
54 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 37 |
115 A systematic review on the efficacy of cytoreductive surgery combined with perioperative chemotherapy for diffuse malignant peritoneal mesothelioma: An evolution of treatment strategies
|
Yan, T.D.
|
|
2006
|
54 |
S1 |
p. S29-
1 p.
|
artikel
|
| 38 |
231 Atypical mesothelial cell proliferations: Separating mesothelioma from reactive mesothelial hyperplasia
|
Colby, T.V.
|
|
2006
|
54 |
S1 |
p. S56-
1 p.
|
artikel
|
| 39 |
39 Australia: Wittenoom and beyond
|
Klerk, N. de
|
|
2006
|
54 |
S1 |
p. S10-
1 p.
|
artikel
|
| 40 |
Author Index
|
|
|
2006
|
54 |
S1 |
p. S61-S64
4 p.
|
artikel
|
| 41 |
100 Bax and Bak immunoreactivity in malignant pleural mesothelioma (MPM)
|
Klabatsa, A.
|
|
2006
|
54 |
S1 |
p. S24-
1 p.
|
artikel
|
| 42 |
161 Bcl-2 family members in mesothelioma
|
Lind, M.
|
|
2006
|
54 |
S1 |
p. S39-
1 p.
|
artikel
|
| 43 |
141 Benign neoplasms of the pleura in the structure of mesothelioma incidence
|
Grinberg, L.M.
|
|
2006
|
54 |
S1 |
p. S35-
1 p.
|
artikel
|
| 44 |
229 Biocompatible, hydrophilic, supramolecular carbon nanoparticles for cell delivery
|
Lau, B.W.
|
|
2006
|
54 |
S1 |
p. S55-S56
2 p.
|
artikel
|
| 45 |
7 Biomarkers for malignant mesothelioma
|
Creaney, J.
|
|
2006
|
54 |
S1 |
p. S2-
1 p.
|
artikel
|
| 46 |
96 Bortezomib accelerates BAX BAK dependent mitochondrial depolarization in malignant pleural mesothelioma cells
|
Chacko, A.
|
|
2006
|
54 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 47 |
189 Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed-induced cell death
|
Min, S.
|
|
2006
|
54 |
S1 |
p. S46-
1 p.
|
artikel
|
| 48 |
208 Calponin-targeting oncolytic Herpes simplex virus (HSV-1) as a novel therapeutic agent for sarcomatous mesothelioma
|
Takahashi, K.
|
|
2006
|
54 |
S1 |
p. S51-
1 p.
|
artikel
|
| 49 |
13 Cell signaling and transcription factor activation by asbestos
|
Mossman, B.
|
|
2006
|
54 |
S1 |
p. S4-
1 p.
|
artikel
|
| 50 |
56 Chemokine receptors are rarely expressed on malignant or benign mesothelial cells
|
Davidson, B.
|
|
2006
|
54 |
S1 |
p. S14-
1 p.
|
artikel
|
| 51 |
5 Chemoprevention as an approach to control of carcinoma of the lung and mesothelioma
|
Sporn, M.
|
|
2006
|
54 |
S1 |
p. S2-
1 p.
|
artikel
|
| 52 |
97 Cisplatin-induced apoptosis in malignant pleural mesothelioma cells involves p53 but not p14ARF
|
Hopkins-Donaldson, S.
|
|
2006
|
54 |
S1 |
p. S24-
1 p.
|
artikel
|
| 53 |
26 Clinico-pathological features of murine mesothelioma induced by natural or synthetic fibers
|
Andujar, P.
|
|
2006
|
54 |
S1 |
p. S7-
1 p.
|
artikel
|
| 54 |
145 Clinico-pathologic analysis of malignant mesothelioma in Korea
|
Jung, S.
|
|
2006
|
54 |
S1 |
p. S36-
1 p.
|
artikel
|
| 55 |
190 Combination chemotherapy: Moving beyond pemetrexed
|
van Meerbeeck, J.P.
|
|
2006
|
54 |
S1 |
p. S46-
1 p.
|
artikel
|
| 56 |
202 Combination chemotherapy with methotrexate, irinotecan, and doxorubicin in malignant pleural mesothelioma: A phase II study
|
Kuribayashi, K.
|
|
2006
|
54 |
S1 |
p. S49-
1 p.
|
artikel
|
| 57 |
157 Combination of cell-surface and soluble mesothelin expressions are required to discern epithelioid mesothelioma cells
|
Sapede, C.
|
|
2006
|
54 |
S1 |
p. S39-
1 p.
|
artikel
|
| 58 |
45 Combining immunotherapy with chemotherapy to treat mice with mesothelioma
|
Lake, R.A.
|
|
2006
|
54 |
S1 |
p. S12-
1 p.
|
artikel
|
| 59 |
214 COX-2 specific inhibitors demonstrate a cytotoxic effect independent of COX-2 protein status in vitro
|
O'Kaneq, S.L.
|
|
2006
|
54 |
S1 |
p. S52-
1 p.
|
artikel
|
| 60 |
117 Critical analysis of nuclear size as an assessment of prognosis in diffuse malignant peritoneal mesothelioma
|
Yan, T.D.
|
|
2006
|
54 |
S1 |
p. S29-
1 p.
|
artikel
|
| 61 |
91 Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in hamsters
|
Kroczynska, B.
|
|
2006
|
54 |
S1 |
p. S22-
1 p.
|
artikel
|
| 62 |
232 Current status of immunohistochemical studies for the diagnosis of mesothelioma
|
Gown, A.M.
|
|
2006
|
54 |
S1 |
p. S56-
1 p.
|
artikel
|
| 63 |
14 Debate: Does SV40 play a causative role in mesothelial cell carcinogenesis? Yes!
|
Gazdar, A.F.
|
|
2006
|
54 |
S1 |
p. S4-
1 p.
|
artikel
|
| 64 |
172 Debate: Surgery for malignant pleural mesothelioma: A guaranteed complete response
|
Flores, R.
|
|
2006
|
54 |
S1 |
p. S42-
1 p.
|
artikel
|
| 65 |
15 Debate: SV40 as a significant carcinogen in human mesothelioma and other cancers: An increasingly dubious hypothesis
|
Ladanyi, M.
|
|
2006
|
54 |
S1 |
p. S4-
1 p.
|
artikel
|
| 66 |
171 Debate: There is no role for radical surgery in the management of pleural mesothelioma
|
Treasure, T.
|
|
2006
|
54 |
S1 |
p. S42-
1 p.
|
artikel
|
| 67 |
52 Dendritic cell-based immunotherapy for malignant pleural mesothelioma
|
Hegmans, J.
|
|
2006
|
54 |
S1 |
p. S13-
1 p.
|
artikel
|
| 68 |
29 Design issues in phase II/III clinical trials in mesothelioma
|
Stephens, R.
|
|
2006
|
54 |
S1 |
p. S7-
1 p.
|
artikel
|
| 69 |
76 Developing a national resource centre for mesothelioma in the UK
|
Darlison, L.
|
|
2006
|
54 |
S1 |
p. S19-
1 p.
|
artikel
|
| 70 |
185 Developing a program for postoperative IMRT in mesothelioma patients following pleurectomy plus phototherapy
|
Feigen, M.
|
|
2006
|
54 |
S1 |
p. S45-
1 p.
|
artikel
|
| 71 |
81 Development of a computer method for volumetric response assessment in mesothelioma
|
Zhao, B.
|
|
2006
|
54 |
S1 |
p. S20-
1 p.
|
artikel
|
| 72 |
21 Development of a malignant mesothelioma model with defined genetic elements
|
Saitoh, M.
|
|
2006
|
54 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 73 |
9 Diagnostic and prognostic utility of soluble mesothelin-related peptides in malignant pleural mesothelioma
|
Grigoriu, B.
|
|
2006
|
54 |
S1 |
p. S3-
1 p.
|
artikel
|
| 74 |
239 Diagnostic utility of GLUT-1 expression in the differential diagnosis between reactive mesothelium and malignant mesothelioma
|
Kato, Y.
|
|
2006
|
54 |
S1 |
p. S58-
1 p.
|
artikel
|
| 75 |
235 Diagnostic value of proliferative markers Ki-67 and Repp 86 in distinguishing between malignant and benign mesothelial proliferations
|
Mohammadtaheri, Z.
|
|
2006
|
54 |
S1 |
p. S57-
1 p.
|
artikel
|
| 76 |
238 Differentiating between malignant mesothelioma and squamous cell carcinoma: An immunohistochemical study
|
Chang, T.
|
|
2006
|
54 |
S1 |
p. S58-
1 p.
|
artikel
|
| 77 |
112 Diffuse malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Experience of NCI of Milan
|
Deraco, M.
|
|
2006
|
54 |
S1 |
p. S28-
1 p.
|
artikel
|
| 78 |
151 Discovery and validation of novel serological biomarkers of mesothelioma
|
Vachani, A.
|
|
2006
|
54 |
S1 |
p. S37-
1 p.
|
artikel
|
| 79 |
102 DNA copy number profiling in malignant pleural mesothelioma by array CGH
|
Lindholm, P.
|
|
2006
|
54 |
S1 |
p. S25-
1 p.
|
artikel
|
| 80 |
147 DNA methylation profile of 28 candidate marker loci in malignant mesothelioma
|
Tsou, J.A.
|
|
2006
|
54 |
S1 |
p. S36-
1 p.
|
artikel
|
| 81 |
80 Early response evaluation in malignant pleural mesothelioma by positron emission tomography with 18F-fluorodeoxyglucose
|
Ceresoli, G.L.
|
|
2006
|
54 |
S1 |
p. S19-S20
2 p.
|
artikel
|
| 82 |
218 Effects of insulin-like growth factor binding protein-3 on human malignant pleural mesothelioma cell growth and apoptosis
|
Miraki-Moud, F.
|
|
2006
|
54 |
S1 |
p. S53-
1 p.
|
artikel
|
| 83 |
149 Effects of long-term supplementation with retinol on plasma, malignant mesothelioma, lung cancer and potential side-effects in the Wittenoom cohort
|
Alfonso, H.
|
|
2006
|
54 |
S1 |
p. S37-
1 p.
|
artikel
|
| 84 |
57 Efficient induction of mesothelioma-specific cytotoxic T cell responses by cross presentation of apoptotic HSP70-overexpressing mesothelioma cells by dendritic cells
|
Ebstein, F.
|
|
2006
|
54 |
S1 |
p. S14-
1 p.
|
artikel
|
| 85 |
105 Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
|
Usami, N.
|
|
2006
|
54 |
S1 |
p. S25-
1 p.
|
artikel
|
| 86 |
130 Exposure to polio vaccine possibly contaminated with simian virus 40 and subsequent risk of malignant mesothelioma
|
Kjærheim, K.
|
|
2006
|
54 |
S1 |
p. S32-
1 p.
|
artikel
|
| 87 |
95 Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression
|
Sivertsen, S.
|
|
2006
|
54 |
S1 |
p. S23-
1 p.
|
artikel
|
| 88 |
179 Extrapleural pneumonectomy with adjuvant chemo-radiotherapy for treatment of malignant pleural mesothelioma
|
Rahman, A.R.M.A.
|
|
2006
|
54 |
S1 |
p. S43-S44
2 p.
|
artikel
|
| 89 |
2 Familial clustering of mesothelioma in subjects exposed to crocidolite at Wittenoom
|
de Klerk, N.
|
|
2006
|
54 |
S1 |
p. S1-
1 p.
|
artikel
|
| 90 |
82 FDG PET/CT in malignant pleural mesothelioma: Is there a histological difference between hot and cold areas?
|
Kestenholz, P.
|
|
2006
|
54 |
S1 |
p. S20-
1 p.
|
artikel
|
| 91 |
30 Functional and patient-rated endpoints in clinical trials
|
Nowak, A.
|
|
2006
|
54 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 92 |
17 Gene expression profiling in an SV40 large T antigen expressing transgenic mouse mesothelioma model. Implications for a role for SV40 in human mesothelioma?
|
Robinson, C.
|
|
2006
|
54 |
S1 |
p. S5-
1 p.
|
artikel
|
| 93 |
62 Gene expression profiling of malignant peritoneal mesothelioma identifies novel targets for therapeutic intervention
|
Varghese, S.
|
|
2006
|
54 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 94 |
8 Genomics for biomarker detection in mesothelioma
|
Pass, H.
|
|
2006
|
54 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 95 |
36 Health effects among World Trade Center responders
|
Levin, S.M.
|
|
2006
|
54 |
S1 |
p. S10-
1 p.
|
artikel
|
| 96 |
209 Histone deacetylase inhibitors
|
Sharma, S.
|
|
2006
|
54 |
S1 |
p. S51-
1 p.
|
artikel
|
| 97 |
53 Identifying and targeting a spectrum of internalizing cell surface antigens expressed by mesothelioma
|
Liu, B.
|
|
2006
|
54 |
S1 |
p. S13-
1 p.
|
artikel
|
| 98 |
217 IGF pathway activation in mesothelioma
|
Kratzke, R.A.
|
|
2006
|
54 |
S1 |
p. S53-
1 p.
|
artikel
|
| 99 |
77 Imaging malignant pleural mesothelioma: Clinical applications and challenges
|
Entwisle, J.
|
|
2006
|
54 |
S1 |
p. S19-
1 p.
|
artikel
|
| 100 |
54 Immune profile of peripheral and pleural fluid T cells in alignant mesothelioma and pleural metastasis of adenocarcinoma
|
Scherpereel, A.
|
|
2006
|
54 |
S1 |
p. S14-
1 p.
|
artikel
|
| 101 |
240 Immunocytochemistry with ten commercially available antibodies in adenocarcinoma cells, malignant or reactive mesothelial cells in serous effusions
|
Kamei, T.
|
|
2006
|
54 |
S1 |
p. S58-
1 p.
|
artikel
|
| 102 |
186 Impact of integrated PET-CT on the selection of patients with malignant pleural mesothelioma for radical surgery (extrapleural pneumonectomy)
|
Lang-Lazdunski, L.
|
|
2006
|
54 |
S1 |
p. S45-
1 p.
|
artikel
|
| 103 |
181 Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma
|
de Perrot, M.
|
|
2006
|
54 |
S1 |
p. S44-
1 p.
|
artikel
|
| 104 |
75 Increased pleural fluid ADA level in patients with malignant mesothelioma: A potential predictor for the outcome of talc pleurodesis
|
Yildirim, H.
|
|
2006
|
54 |
S1 |
p. S18-
1 p.
|
artikel
|
| 105 |
180 Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): A single center experience
|
Rea, F.
|
|
2006
|
54 |
S1 |
p. S44-
1 p.
|
artikel
|
| 106 |
175 Induction chemotherapy with cisplatine/gemcitabine compared to cisplatin/pemetrexed followed by extrapleural pneumonectomy for malignant pleural mesothelioma
|
Opitz, I.
|
|
2006
|
54 |
S1 |
p. S42-S43
2 p.
|
artikel
|
| 107 |
101 Inhibition of survivin and aurora B kinase radiosensitizes mesothelioma cells by enhancing mitotic arrests
|
Kim, K.W.
|
|
2006
|
54 |
S1 |
p. S24-
1 p.
|
artikel
|
| 108 |
173 Integrating chemotherapy into multi-modality treatment
|
Stahel, R.
|
|
2006
|
54 |
S1 |
p. S42-
1 p.
|
artikel
|
| 109 |
116 In vitro drug resistance levels do not correlate with prognosis in patients with peritoneal mesothelioma
|
Patel, K.
|
|
2006
|
54 |
S1 |
p. S29-
1 p.
|
artikel
|
| 110 |
31 Is there a correlation between pathologic response and radiographic response and what does this mean?
|
Fennell, D.
|
|
2006
|
54 |
S1 |
p. S8-
1 p.
|
artikel
|
| 111 |
20 Local recurrence model of malignant pleural mesothelioma and investigation of local adjuvant treatment after surgery
|
Schmitt-Opitz, I.
|
|
2006
|
54 |
S1 |
p. S5-
1 p.
|
artikel
|
| 112 |
19 Loss of functional Arf predisposes mice to asbestos-induced mesothelioma
|
Altomare, D.A.
|
|
2006
|
54 |
S1 |
p. S5-
1 p.
|
artikel
|
| 113 |
155 Low-dose computed tomography in prior asbestos-exposed workers: Assessment of pleural plaques and screening for lung cancer and malignant mesothelioma
|
Bayanati, H.
|
|
2006
|
54 |
S1 |
p. S38-
1 p.
|
artikel
|
| 114 |
11 Low-dose computed tomography in prior asbestos workers
|
Roberts, H.
|
|
2006
|
54 |
S1 |
p. S3-
1 p.
|
artikel
|
| 115 |
154 Low-dose computed tomography in workers previously exposed to asbestos: Detection of parenchymal lung disease
|
Patsios, D.
|
|
2006
|
54 |
S1 |
p. S38-
1 p.
|
artikel
|
| 116 |
136 Lung burden in the Nottingham gas mask cohort
|
Berry, G.
|
|
2006
|
54 |
S1 |
p. S34-
1 p.
|
artikel
|
| 117 |
177 Lung-sparing intrapleural and systemic chemotherapy plus intrapleural radiation for pleural mesothelioma: The Columbia protocol
|
Taub, R.N.
|
|
2006
|
54 |
S1 |
p. S43-
1 p.
|
artikel
|
| 118 |
131 Malignant mesothelioma as a second primary malignancy
|
Burgers, S.
|
|
2006
|
54 |
S1 |
p. S32-S33
2 p.
|
artikel
|
| 119 |
67 Malignant mesothelioma (MM) and cachexia. Description of body composition changes in 27 patients receiving chemotherapy and/or thalidomide treatment
|
Pavlakis, N.
|
|
2006
|
54 |
S1 |
p. S17-
1 p.
|
artikel
|
| 120 |
244 Malignant mesothelioma with signet ring cell formation: A very rare presentation
|
Beder, S.
|
|
2006
|
54 |
S1 |
p. S59-
1 p.
|
artikel
|
| 121 |
245 Malignant tumor with bone formation in a man from Karain village: Mesothelioma or sarcoma?
|
Hillerdal, G.
|
|
2006
|
54 |
S1 |
p. S59-
1 p.
|
artikel
|
| 122 |
123 Management of complications following extrapleural pneumonectomy (EPP)
|
Dienemann, H.C.
|
|
2006
|
54 |
S1 |
p. S31-
1 p.
|
artikel
|
| 123 |
68 Managing effusions: When and how to intervene
|
Miller, D.L.
|
|
2006
|
54 |
S1 |
p. S17-
1 p.
|
artikel
|
| 124 |
66 Managing pain in mesothelioma
|
Zuurmond, W.W.A.
|
|
2006
|
54 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 125 |
143 Mesothelioma in Russia: Review of 3,259 published cases
|
Kashansky, S.V.
|
|
2006
|
54 |
S1 |
p. S35-
1 p.
|
artikel
|
| 126 |
42 Mesothelioma in Turkey: A rural disease
|
Metintas, M.
|
|
2006
|
54 |
S1 |
p. S11-
1 p.
|
artikel
|
| 127 |
107 Mesotheliomas of the pericardium and tunica vaginalis
|
Hassan, R.
|
|
2006
|
54 |
S1 |
p. S27-
1 p.
|
artikel
|
| 128 |
38 Mesothelioma update for Libby, Montana: Occupational and non-occupationa
|
Case, B.W.
|
|
2006
|
54 |
S1 |
p. S10-
1 p.
|
artikel
|
| 129 |
228 MET in mesothelioma: Mutational screening, phosphorylation status, and sensitivity to the MET inhibitor PHA-665752
|
Shimizu, S.
|
|
2006
|
54 |
S1 |
p. S55-
1 p.
|
artikel
|
| 130 |
92 Microarray of normal mesothelium and mesothelioma - visceral and parietal pleura has distinct gene expression profile-consequences for oncogenesis of mesothelioma?
|
Røe, O.D.
|
|
2006
|
54 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 131 |
83 Molecular bioprobes for imaging malignant mesothelioma
|
Misri, R.
|
|
2006
|
54 |
S1 |
p. S20-
1 p.
|
artikel
|
| 132 |
233 Molecular studies in diffuse malignant mesothelioma of the pleura
|
Galateau-Sallé, F.
|
|
2006
|
54 |
S1 |
p. S56-S57
2 p.
|
artikel
|
| 133 |
224 Molecular targeting of malignant pleural mesothelioma by c-Met and ROS modulation
|
Jagadeeswaran, R.
|
|
2006
|
54 |
S1 |
p. S54-
1 p.
|
artikel
|
| 134 |
24 Monitoring tumor growth by imaging of a human mesothelioma murine model
|
Bertino, P.
|
|
2006
|
54 |
S1 |
p. S6-
1 p.
|
artikel
|
| 135 |
230 Morphologic diagnostic criteria of mesothelioma
|
Cagle, P.T.
|
|
2006
|
54 |
S1 |
p. S56-
1 p.
|
artikel
|
| 136 |
234 MUC1 in malignant mesothelioma
|
Creaney, J.
|
|
2006
|
54 |
S1 |
p. S57-
1 p.
|
artikel
|
| 137 |
129 Multi-center clinical trials for peritoneal mesothelioma: Can they be done and what are the questions to be answered?
|
Hassan, R.
|
|
2006
|
54 |
S1 |
p. S32-
1 p.
|
artikel
|
| 138 |
174 Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)
|
Krug, L.M.
|
|
2006
|
54 |
S1 |
p. S42-
1 p.
|
artikel
|
| 139 |
111 Multimodality regional therapy for peritoneal mesothelioma
|
Chabot, J.A.
|
|
2006
|
54 |
S1 |
p. S28-
1 p.
|
artikel
|
| 140 |
51 Murine mesothelioma treatment with peritumoral injections of CpG alone or combined with CD40 ligand
|
Kornbluth, R.S.
|
|
2006
|
54 |
S1 |
p. S13-
1 p.
|
artikel
|
| 141 |
223 Nanoporous spheres for drug delivery in mesotheliomax
|
Ramos-Nino, M.
|
|
2006
|
54 |
S1 |
p. S54-
1 p.
|
artikel
|
| 142 |
187 New insights into the mechanisms of action of pemetrexed in mesothelioma
|
Goldman, I.D.
|
|
2006
|
54 |
S1 |
p. S45-
1 p.
|
artikel
|
| 143 |
89 NF-kB provides a survival signal to human mesothelial and mesothelioma cells exposed to asbestos fibers
|
Barbone, D.
|
|
2006
|
54 |
S1 |
p. S22-
1 p.
|
artikel
|
| 144 |
139 Occupational asbestos exposure, possible mesothelioma and reimbursement
|
Baas, P.
|
|
2006
|
54 |
S1 |
p. S34-
1 p.
|
artikel
|
| 145 |
121 Operative complications: Diagnosis and treatment
|
Opitz, I.
|
|
2006
|
54 |
S1 |
p. S30-
1 p.
|
artikel
|
| 146 |
88 Oxidative stress gene modulation in pleural mesothelioma as assessed by microarray in vitro, ex-vivo, and in-situ analysis
|
Rihn, B.H.
|
|
2006
|
54 |
S1 |
p. S21-
1 p.
|
artikel
|
| 147 |
246 Pathological study of malignant pleural mesothelioma resected with extrapleural pneumonectomy
|
Hiroshima, K.
|
|
2006
|
54 |
S1 |
p. S59-
1 p.
|
artikel
|
| 148 |
86 Pathway signatures of biphasic and epithelial mesothelioma identify the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
|
Borczuk, A.C.
|
|
2006
|
54 |
S1 |
p. S21-
1 p.
|
artikel
|
| 149 |
71 Patients' and carers' experience of mesothelioma
|
Clayson, H.
|
|
2006
|
54 |
S1 |
p. S18-
1 p.
|
artikel
|
| 150 |
188 Pemetrexed but not vinorelbine and cisplatin cytotoxicity is enhanced by COX-2 inhibitors in mesothelioma cell lines
|
O'Kane, S.L.
|
|
2006
|
54 |
S1 |
p. S45-S46
2 p.
|
artikel
|
| 151 |
203 Pemetrexed in combination with carboplatin for the treatment of patients with malignant mesothelioma
|
Papi, M.
|
|
2006
|
54 |
S1 |
p. S49-
1 p.
|
artikel
|
| 152 |
191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma
|
Ceresoli, G.L.
|
|
2006
|
54 |
S1 |
p. S46-
1 p.
|
artikel
|
| 153 |
197 Pemetrexed (MTA) and carboplatin (CBDCA) in advanced pleural mesothelioma (MPM): Evaluation of the activity and toxicity in a series of 178 chemonaive patients
|
Bruno, C.
|
|
2006
|
54 |
S1 |
p. S48-
1 p.
|
artikel
|
| 154 |
192 Pemetrexed second-line treatment in malignant pleural mesothelioma following platinum-based first-line treatment
|
Sorensen, J.B.
|
|
2006
|
54 |
S1 |
p. S46-S47
2 p.
|
artikel
|
| 155 |
119 Pericardial and diaphragmatic reconstruction
|
Batirel, H.
|
|
2006
|
54 |
S1 |
p. S29-S30
2 p.
|
artikel
|
| 156 |
127 Peritoneal mesothelioma: Treatment options for patients who are not candidates for surgery
|
Verschraegen, C.F.
|
|
2006
|
54 |
S1 |
p. S31-
1 p.
|
artikel
|
| 157 |
211 Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307
|
Jänne, P.A.
|
|
2006
|
54 |
S1 |
p. S51-S52
2 p.
|
artikel
|
| 158 |
114 Phase II trial of vinorelbine chemotherapy in patients with malignant peritoneal mesothelioma
|
Steele, J.P.C.
|
|
2006
|
54 |
S1 |
p. S28-S29
2 p.
|
artikel
|
| 159 |
12 Plasticity of the mesothelium: A stem cell in the midst?
|
Mutsaers, S.
|
|
2006
|
54 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 160 |
37 Pleural abnormalities and exposure to asbestos-contaminated vermiculite from Libby, Montana: A twenty year follow-up study
|
Lockey, J.E.
|
|
2006
|
54 |
S1 |
p. S10-
1 p.
|
artikel
|
| 161 |
126 Pleurectomy/decortication for malignant pleural mesothelioma: Technique and comments
|
Pass, H.
|
|
2006
|
54 |
S1 |
p. S31-
1 p.
|
artikel
|
| 162 |
69 Pleurodesis in follow-up and treatment of malignant pleural mesothelioma patients
|
Ak, G.
|
|
2006
|
54 |
S1 |
p. S17-
1 p.
|
artikel
|
| 163 |
3 Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study
|
Dianzani, I.
|
|
2006
|
54 |
S1 |
p. S1-
1 p.
|
artikel
|
| 164 |
109 Potential of survivin as a new therapeutic target in diffuse malignant mesothelioma of the peritoneum
|
Zaffaroni, N.
|
|
2006
|
54 |
S1 |
p. S27-
1 p.
|
artikel
|
| 165 |
27 Potential pitfalls in the evaluation of new drugs for mesothelioma: Lessons from the past
|
Baas, P.
|
|
2006
|
54 |
S1 |
p. S7-
1 p.
|
artikel
|
| 166 |
216 Preclinical evaluation of histone deacetylase inhibitors in malignant mesothelioma
|
Sharma, S.
|
|
2006
|
54 |
S1 |
p. S52-S53
2 p.
|
artikel
|
| 167 |
205 Preclinical studies of the proteosome inhibtor bortezomib (velcade) in malignant pleural mesothelioma (MPM)
|
Gordon, G.J.
|
|
2006
|
54 |
S1 |
p. S50-
1 p.
|
artikel
|
| 168 |
152 Pre-diagnostic soluble mesothelin related protein, CA125, CYFRA 21-1 and risk of mesothelioma: A case-control study
|
Røe, O.D.
|
|
2006
|
54 |
S1 |
p. S37-S38
2 p.
|
artikel
|
| 169 |
150 Predictive and/or diagnostic significance of serum soluble mesothelin related proteins (SMR) in asbestos-related pleural malignant mesothelioma: Follow-up of a large population of workers previously exposed to asbestos
|
Cristaudo, A.
|
|
2006
|
54 |
S1 |
p. S37-
1 p.
|
artikel
|
| 170 |
124 Preoperative assessment and criteria for patient selection
|
Lang-Lazdunski, L.
|
|
2006
|
54 |
S1 |
p. S31-
1 p.
|
artikel
|
| 171 |
169 Pre-operative staging with CT/PET
|
Troung, M.
|
|
2006
|
54 |
S1 |
p. S41-
1 p.
|
artikel
|
| 172 |
28 Prognosis of malignant pleural mesothelioma: Subtype more important than stage. A study from the Nordic Mesothelioma Groups
|
Hillerdal, G.
|
|
2006
|
54 |
S1 |
p. S7-
1 p.
|
artikel
|
| 173 |
144 Prognostic factors and survival of malignant mesothelioma in Korea
|
Kim, H.R.
|
|
2006
|
54 |
S1 |
p. S36-
1 p.
|
artikel
|
| 174 |
63 Prognostic gene ratio test for mesothelioma validated in a prospective clinical trial
|
Bueno, R.
|
|
2006
|
54 |
S1 |
p. S16-
1 p.
|
artikel
|
| 175 |
241 Prognostic value of fascin immunoreactivity in peritoneal mesothelioma
|
Borczuk, A.C.
|
|
2006
|
54 |
S1 |
p. S58-
1 p.
|
artikel
|
| 176 |
134 Projected mesothelioma incidence in men in New South Wales, Australia
|
Berry, G.
|
|
2006
|
54 |
S1 |
p. S33-
1 p.
|
artikel
|
| 177 |
236 Prolonged survival in malignant mesothelioma: A study of nineteen cases
|
Galateau-Sallé, F.
|
|
2006
|
54 |
S1 |
p. S57-
1 p.
|
artikel
|
| 178 |
113 Prospective evaluation of qualtiy of life after tumor cytoreduction and intraperitoneal chemotherapy in patients with mesothelioma and other peritoneal surface malignancies
|
Alexander, R.
|
|
2006
|
54 |
S1 |
p. S28-
1 p.
|
artikel
|
| 179 |
204 Proteasome inhibitors for treatment of malignant mesothelioma
|
Fennel, D.
|
|
2006
|
54 |
S1 |
p. S50-
1 p.
|
artikel
|
| 180 |
61 Proteomic methods to identify novel therapeutic targets in malignant mesothelioma
|
Jänne, P.A.
|
|
2006
|
54 |
S1 |
p. S15-
1 p.
|
artikel
|
| 181 |
133 Quantifying the risks of mesothelioma and lung cancer from environmental crocidolite exposure in Da-yao, China
|
Cheng, T.D.
|
|
2006
|
54 |
S1 |
p. S33-
1 p.
|
artikel
|
| 182 |
137 Quantitative estimation of the risk of lung cancer and pleural mesothelioma among automobile mechanics in France
|
Imbernon, E.
|
|
2006
|
54 |
S1 |
p. S34-
1 p.
|
artikel
|
| 183 |
106 Ras pathway activation in malignant mesothelioma
|
Patel, M.R.
|
|
2006
|
54 |
S1 |
p. S25-S26
2 p.
|
artikel
|
| 184 |
74 Rates of thromboembolic events (TEE) in patients with mesothelioma
|
Nguyen, D.
|
|
2006
|
54 |
S1 |
p. S18-
1 p.
|
artikel
|
| 185 |
168 Receptor tyrosine kinase pathways and cell survival in mesothelioma
|
Bertino, P.
|
|
2006
|
54 |
S1 |
p. S41-
1 p.
|
artikel
|
| 186 |
159 Re-evaluation of plasma osteopontin as a tumor marker for mesothelioma
|
Shiomi, K.
|
|
2006
|
54 |
S1 |
p. S39-
1 p.
|
artikel
|
| 187 |
163 Regulation of cell survival in malignant pleural mesothelioma by Inhibitor of Apoptosis Proteins
|
Gordon, G.J.
|
|
2006
|
54 |
S1 |
p. S40-
1 p.
|
artikel
|
| 188 |
207 Results of phase I clinical trials of adenoviral interferon-β gene therapy for malignant mesothelioma and malignant pleural effusions
|
Sterman, D.H.
|
|
2006
|
54 |
S1 |
p. S50-S51
2 p.
|
artikel
|
| 189 |
142 Risk assessment of malignant pleural mesothelioma related to a long-term exposure to radiation factors
|
Kashansky, S.V.
|
|
2006
|
54 |
S1 |
p. S35-
1 p.
|
artikel
|
| 190 |
122 Risk factors for major complications after extrapleural pneumonectomy
|
de Perrot, M.
|
|
2006
|
54 |
S1 |
p. S30-
1 p.
|
artikel
|
| 191 |
35 Risk of pleural mesothelioma: A French population-based case-control study (1998-2002)
|
Rolland, P.
|
|
2006
|
54 |
S1 |
p. S9-S10
2 p.
|
artikel
|
| 192 |
227 RNA interference against Hec1 targets malignant mesothelioma (MM)
|
Zhu, Z.B.
|
|
2006
|
54 |
S1 |
p. S55-
1 p.
|
artikel
|
| 193 |
99 Role of notch signaling in human malignant mesothelioma
|
Graziani, I.
|
|
2006
|
54 |
S1 |
p. S24-
1 p.
|
artikel
|
| 194 |
170 Role of preoperative staging procedures using conventional CT scan, FDG-PET-CT-scan fused imaging, and mediastinoscopy compared to surgical-pathological findings in malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy
|
Sorensen, J.B.
|
|
2006
|
54 |
S1 |
p. S41-
1 p.
|
artikel
|
| 195 |
90 Semi-quantitative analysis of growth factor gene expression in the lungs and pleura by laser capture microscopy
|
Brody, A.R.
|
|
2006
|
54 |
S1 |
p. S22-
1 p.
|
artikel
|
| 196 |
178 Sequential amifostine and sodium thiosulfate improve renal protection during intracavitary high-dose cisplatin lavage
|
Richards, W.G.
|
|
2006
|
54 |
S1 |
p. S43-
1 p.
|
artikel
|
| 197 |
199 Sequential topoisomerase targeting triplet chemotherapy with irinotecan/cisplatin followed by doxorubicin in patients with malignant pleural mesothelioma: A pilot phase II study
|
Nakano, T.
|
|
2006
|
54 |
S1 |
p. S48-
1 p.
|
artikel
|
| 198 |
158 Serum tumor marker of human asbestos-related mesothelioma: Translational research from a hereditary rat cancer model
|
Hino, O.
|
|
2006
|
54 |
S1 |
p. S39-
1 p.
|
artikel
|
| 199 |
162 Small molecule inhibition of the Bcl-2 family
|
Rosenberg, S.
|
|
2006
|
54 |
S1 |
p. S40-
1 p.
|
artikel
|
| 200 |
156 Soluble mesothelin-related protein (SMRP) is a useful biomarker for malignant mesothelioma in Japan
|
Fukuoka, K.
|
|
2006
|
54 |
S1 |
p. S38-S39
2 p.
|
artikel
|
| 201 |
32 South Africa: The first link between asbestos and mesothelioma, but not the last word?
|
teWaterNaude, J.
|
|
2006
|
54 |
S1 |
p. S9-
1 p.
|
artikel
|
| 202 |
247 Spontaneous regression of diffuse malignant pleural mesothelioma (MPM) with no treatment: Two case reports
|
Klabatsa, A.
|
|
2006
|
54 |
S1 |
p. S59-S60
2 p.
|
artikel
|
| 203 |
84 Spontaneous regression of diffuse malignant pleural mesothelioma with no treatment: Two case reports
|
Klabatsa, A.
|
|
2006
|
54 |
S1 |
p. S20-
1 p.
|
artikel
|
| 204 |
128 Staging of peritoneal mesothelioma?
|
Sugarbaker, P.
|
|
2006
|
54 |
S1 |
p. S32-
1 p.
|
artikel
|
| 205 |
55 Stimulation of macrophage toxicity for mesothelioma cells by anti-CD14 antibody
|
Philippeaux, M.M.
|
|
2006
|
54 |
S1 |
p. S14-
1 p.
|
artikel
|
| 206 |
184 Successful multimodal treatment in primarily chemo-resistant pleural mesothelioma
|
Bischoff, H.G.
|
|
2006
|
54 |
S1 |
p. S44-S45
2 p.
|
artikel
|
| 207 |
104 SV40 infection can promote full oncogenicity of human mesothelial cells
|
Bocchetta, M.
|
|
2006
|
54 |
S1 |
p. S25-
1 p.
|
artikel
|
| 208 |
23 SV40 oncoproteins and p53 deficiency impair stress-induced mesothelial cell senescence
|
Pietruska, J.R.
|
|
2006
|
54 |
S1 |
p. S6-
1 p.
|
artikel
|
| 209 |
47 Targeting the tumor microenvironment: A novel immunotherapy that cures large mesothelioma tumors by engaging neutrophils, CD8+ T cells and tumor blood vessels
|
Nelson, D.
|
|
2006
|
54 |
S1 |
p. S12-
1 p.
|
artikel
|
| 210 |
215 Targeting thioredoxin reductase - a possible new treatment for malignant mesothelioma
|
Nilsonne, G.
|
|
2006
|
54 |
S1 |
p. S52-
1 p.
|
artikel
|
| 211 |
118 Technical considerations of extrapleural pneumonectomy
|
Sugarbaker, D.J.
|
|
2006
|
54 |
S1 |
p. S29-
1 p.
|
artikel
|
| 212 |
120 Techniques of intra-operative chemotherapy
|
Zellos, L.
|
|
2006
|
54 |
S1 |
p. S30-
1 p.
|
artikel
|
| 213 |
212 TGF-beta inhibition augments adenoviral-IFNbeta (Ad.IFNβ gene therapy in a murine mesothelioma model
|
Kim, S.S.
|
|
2006
|
54 |
S1 |
p. S52-
1 p.
|
artikel
|
| 214 |
196 The current status of mesothelioma clinical trials in Australasia
|
Pavlakis, N.
|
|
2006
|
54 |
S1 |
p. S47-
1 p.
|
artikel
|
| 215 |
195 The current status of mesothelioma clinical trials in Europe
|
Baas, P.
|
|
2006
|
54 |
S1 |
p. S47-
1 p.
|
artikel
|
| 216 |
194 The current status of mesothelioma clinical trials in North America
|
Krug, L.M.
|
|
2006
|
54 |
S1 |
p. S47-
1 p.
|
artikel
|
| 217 |
70 The evaluation of local dissemination on intervention sites in malignant mesothelioma patients and indications for prophylactic radiotherapy
|
Metintas, M.
|
|
2006
|
54 |
S1 |
p. S17-
1 p.
|
artikel
|
| 218 |
78 The evolution of imaging-based tumor response evaluation in mesothelioma
|
Armato, S.G.
|
|
2006
|
54 |
S1 |
p. S19-
1 p.
|
artikel
|
| 219 |
135 The French national mesothelioma surveillance program
|
Goldberg, M.
|
|
2006
|
54 |
S1 |
p. S33-
1 p.
|
artikel
|
| 220 |
34 The global asbestos epidemic and its reflections in the recent Japanese experience
|
Lin, R-T.
|
|
2006
|
54 |
S1 |
p. S9-
1 p.
|
artikel
|
| 221 |
49 The importance of stroma in the development and destruction of cancers
|
Schreiber, H.
|
|
2006
|
54 |
S1 |
p. S12-S13
2 p.
|
artikel
|
| 222 |
65 The management of breathlessness in mesothelioma
|
Booth, S.
|
|
2006
|
54 |
S1 |
p. S16-
1 p.
|
artikel
|
| 223 |
182 The Mesothelioma and Radical Surgery (MARS) trial update
|
Treasure, T.
|
|
2006
|
54 |
S1 |
p. S44-
1 p.
|
artikel
|
| 224 |
132 The mesothelioma epidemic and the hidden asbestos-related lung cancer epidemic
|
Rake, C.
|
|
2006
|
54 |
S1 |
p. S33-
1 p.
|
artikel
|
| 225 |
1 The mesothelioma epidemic in Cappadocia: The gene environment interaction
|
Carbone, M.
|
|
2006
|
54 |
S1 |
p. S1-
1 p.
|
artikel
|
| 226 |
33 The mesothelioma epidemic: Occupational, environmental and spontaneous cases
|
Peto, J.
|
|
2006
|
54 |
S1 |
p. S9-
1 p.
|
artikel
|
| 227 |
72 The nurse's role in mesothelioma
|
Guterz, T.L.
|
|
2006
|
54 |
S1 |
p. S18-
1 p.
|
artikel
|
| 228 |
41 The rising toll of mesothelioma in Egypt
|
Gaafar, R.
|
|
2006
|
54 |
S1 |
p. S11-
1 p.
|
artikel
|
| 229 |
219 The role of c-Met in mesothelioma
|
Ramasamy, J.
|
|
2006
|
54 |
S1 |
p. S53-
1 p.
|
artikel
|
| 230 |
125 The role of invasive staging in determining the management of pleural mesothelioma
|
Friedberg, J.S.
|
|
2006
|
54 |
S1 |
p. S31-
1 p.
|
artikel
|
| 231 |
176 The scientific basis of integrated multimodality regimensx
|
Robinson, B.
|
|
2006
|
54 |
S1 |
p. S43-
1 p.
|
artikel
|
| 232 |
64 The scope of supportive palliative care for malignant mesothelioma in the 21st century
|
Muers, M.
|
|
2006
|
54 |
S1 |
p. S16-
1 p.
|
artikel
|
| 233 |
166 Three-dimensional models of mesothelioma and multi-cellular apoptotic resistance
|
Barbone, D.
|
|
2006
|
54 |
S1 |
p. S40-S41
2 p.
|
artikel
|
| 234 |
87 TNF-α inhibits asbestos induced cytotoxicity via a NF-kB dependent pathway: A possible mechanism for asbestos-induced oncogenesis
|
Yang, H.
|
|
2006
|
54 |
S1 |
p. S21-
1 p.
|
artikel
|
| 235 |
165 TRAIL and damage pathways converge to induce synergistic apoptosis
|
Broaddus, V.C.
|
|
2006
|
54 |
S1 |
p. S40-
1 p.
|
artikel
|
| 236 |
200 Treatment of malignant pleural mesothelioma with gemcitabine, carboplatin and liposomized doxorubicin (Caelyx®): The CCG study from the Nordic mesothelioma groups
|
Hillerdal, G.
|
|
2006
|
54 |
S1 |
p. S48-
1 p.
|
artikel
|
| 237 |
201 Treatment with gemcitabine and vinorelbine (GEMVIN) as second-line chemotherapy in pemetrexed-pretreated patients with malignant pleural mesothelioma (MPM)
|
Zucali, P.A.
|
|
2006
|
54 |
S1 |
p. S48-S49
2 p.
|
artikel
|
| 238 |
140 Trend of mesothelioma morbidity in Sverdlovsk Region of the Russian Federation
|
Kashansky, S.V.
|
|
2006
|
54 |
S1 |
p. S35-
1 p.
|
artikel
|
| 239 |
183 Tri-modality treatment of malignant pleural mesothelioma in Turkey
|
Batirel, H.F.
|
|
2006
|
54 |
S1 |
p. S44-
1 p.
|
artikel
|
| 240 |
22 Tumor infiltrating macrophages in murine malignant mesothelioma: Targeting macrophages for tumor therapy
|
Scott, B.
|
|
2006
|
54 |
S1 |
p. S6-
1 p.
|
artikel
|
| 241 |
225 Tyrosine kinase inhibitor ZD6474 (Zactima) and its effects on malignant mesothelioma cell lines
|
Pier-Giacomo, B.
|
|
2006
|
54 |
S1 |
p. S55-
1 p.
|
artikel
|
| 242 |
108 Understanding the terminology and pathology of peritoneal mesothelioma
|
Roggli, V.
|
|
2006
|
54 |
S1 |
p. S27-
1 p.
|
artikel
|
| 243 |
79 Use of 18F-FDG PET imaging in staging and prediction of survival for malignant pleural mesothelioma (MPM)
|
Nowak, A.K.
|
|
2006
|
54 |
S1 |
p. S19-
1 p.
|
artikel
|
| 244 |
242 Utility of CD138, estrogen receptor and progesterone receptor in the differential diagnosis of peritoneal mesothelioma and ovarian adenocarcinoma
|
Borczuk, A.C.
|
|
2006
|
54 |
S1 |
p. S58-S59
2 p.
|
artikel
|
| 245 |
193 Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a European phase II study
|
Margery, J.
|
|
2006
|
54 |
S1 |
p. S47-
1 p.
|
artikel
|
| 246 |
6 Vitamin A and cancer prevention in workers previously exposed to asbestos in Wittenoom
|
Alfonso, H.
|
|
2006
|
54 |
S1 |
p. S2-
1 p.
|
artikel
|
| 247 |
46 What is the evidence in patients that there is any immune response to mesothelioma and/or that immunotherapy ever works?
|
Robinson, B.
|
|
2006
|
54 |
S1 |
p. S12-
1 p.
|
artikel
|
| 248 |
167 Wnt targeted therapies for mesothelioma
|
Jablons, D.M.
|
|
2006
|
54 |
S1 |
p. S41-
1 p.
|
artikel
|
Tijdschrift beschrijving